Scope, Claims, and US Patent Landscape for Drug Patent US 5,468,755
US 5,468,755 claims timed daily administration of “prolactin-inhibiting compounds” (expressly dopamine agonists in multiple dependent claims) to produce durable metabolic effects tied to prolactin rhythm control. The claim set centers on: (i) insulin resistance/hyperinsulinemia/hyperglycemia/glucose tolerance improvements, (ii) “resetting” or modifying prolactin rhythm and related neural phase oscillations by dosing at a clock time relative to the prolactin peak in a lean, insulin-sensitive subject of the same species/sex, and (iii) extending persistence of effects after cessation. Bromocriptine and a defined list of ergoline-class dopamine agonists are repeatedly enumerated as exemplary actives.
What is the core invention claimed?
The patent’s independent claim themes are not just “use a dopamine agonist for diabetes.” They require a dosing regimen that is time-structured around prolactin physiology and, in multiple places, a durable post-treatment effect.
Independent claim clusters (by functional scope):
-
Glucose metabolism modification via timed daily prolactin inhibition
- Claim 1: timed daily prolactin-inhibiting compound to decrease insulin resistance, reduce hyperinsulinemia, increase glucose tolerance, and/or reduce hyperglycemia.
- Claims 11-12: “modify or resetting the prolactin rhythm” in insulin-insensitive/diabetic subjects via once-daily administration at a predetermined time designed to lower daytime prolactin to match a lean insulin-sensitive profile (with glucose endpoints).
-
Timing constraint tied to prolactin peak in a lean insulin-sensitive reference
- Claim 8 and Claim 19: administer dopamine agonist 1 to 10 hours after the prolactin bloodstream level peaks in a lean insulin-sensitive subject of same species and sex.
- This reference-peak timing appears as a key narrowing feature distinguishing the regimen from generic diabetes pharmacotherapy.
-
Durability / persistence after discontinuation
- Claim 3: at least one metabolic modification persists for at least one month after cessation of dopamine agonist.
- Claim 15 and Claim 21 similarly require long-term persistence after cessation.
-
Dosage and duration ranges for dopamine agonists
- Claim 4 / 6 / 14 / 19 / 20 / 22 / 35: dopamine agonist dose about 3 to about 100 micrograms per pound of body weight.
- Claim 5 / 7 / 16 / 36: administration period about 10 to 150 days (and dependent versions specifying 30 to 150 days).
- Claim 8 / 19: once-daily dosing and timing relative to prolactin peak.
-
Mechanistic framing: neural phase oscillations (prolactin and glucocorticosteroid)
- Claim 22: period is sufficient to modify and reset neural phase oscillations controlling prolactin and glucocorticosteroid levels.
- Claim 27 and Claim 34: analogous reset/modify language extending to glucocorticosteroid rhythm control.
-
Extension to lipid metabolism / body fat stores
- Claims 30-39: timed prolactin inhibition to decrease or increase body fat stores, including persistence after cessation and neural oscillation reset language.
What are the claimed actives and how specific is the composition scope?
The patent’s chemical scope is expressed primarily through “prolactin-inhibiting compound” and then tightened via dependent claims to dopamine agonists and an enumerated selection list.
Dopamine agonist requirement (explicit dependent claims):
- Claim 2: prolactin-inhibiting compound is a dopamine agonist.
- Claim 13, 20, 26, 32: similarly specify dopamine agonists in other independent-theme claims.
Enumerated dopamine agonist list (reappearing across claims):
Claims 9, 17, 23, 28, 29, 33, 38 each select from:
- 6-methyl-8-beta-carbobenzyloxy-aminoethyl-10 alpha-ergoline
- 1,6-dimethyl-8-beta-carbobenzyloxy-aminoethyl-10 alpha-ergoline
- 8-acylaminoergolenes
- ergocornine
- 9,10-dihydroergocornine
- bromocriptine
- D-2-halo-6-alkyl-8-substituted ergolines
Bromocriptine is explicitly covered:
- Claims 10, 18, 24, 29, 39 include bromocriptine as the compound.
Practical scope implication:
To land inside dependent claim layers, an accused regimen must align with both the time-structured prolactin/rhythm concept and an ergoline/dopamine-agonist identity as set out in the enumerated list (with bromocriptine being the most obvious and repeatedly called out example).
What do the claims require for “timed daily basis” and the prolactin peak reference?
The claim language introduces two distinct timing concepts:
-
Generic timed daily basis (less strict):
- Claim 1: “administering … on a timed daily basis” (no explicit clock-time constraint relative to prolactin peak in this independent claim).
-
Clock-time designed to shift prolactin rhythm (more specific):
- Claim 12: predetermined time so daytime prolactin level decreases at a time corresponding to low daytime prolactin level of lean insulin-sensitive subject.
- Claim 8 and Claim 19: specifically administer 1 to 10 hours after prolactin peaks in a lean insulin-sensitive reference subject (same species and sex; in Claim 19, the human reference is pathology-free).
When timing is critical:
Dependent claims 8 and 19 embed a quantitative timing window tied to a physiologic reference. That type of limitation commonly becomes a key differentiator in infringement analyses against broader “prolactin suppression” approaches.
What metabolic endpoints are claimed as “modifications”?
The patent uses “at least one of” lists, but the endpoints are consistent across the glucose and lipid sections.
Glucose metabolism endpoints:
- Decrease insulin resistance (Claims 1, 11, 19, 25)
- Reduction of hyperinsulinemia (Claims 1, 11, 19)
- Increase in glucose tolerance (Claims 1, 11)
- Reduction of hyperglycemia (Claims 1, 11, 19, 25, 12)
- Additional persistence language appears as a durability constraint (Claims 3, 15, 21)
Lipid/body-fat endpoints:
- Decrease in body fat stores or increase in body fat stores (Claims 30, 37)
Dose and duration constraints: how narrow are they?
The patent hardwires dose and treatment period ranges across multiple dependent claims, which can materially affect both claim construction and design-around space.
Dose range repeated across dopamine agonist-dependent claims:
- 3 to 100 micrograms per pound of body weight (Claims 4, 6, 14, 19, 35)
Duration ranges repeated:
- 10 to 150 days (Claims 5)
- 30 to 150 days (Claims 7, 16, 36)
Dosing frequency:
- Once daily is specified in many dopamine agonist claims (Claims 4, 6, 8, 11, 12, 13, 14, 16, 19, 20, 25, 26, 32, 36, 37).
Persistence after cessation: what does the claim require?
Multiple dependent claims add a post-discontinuation durability layer. The patent does not merely require acute glucose improvement; it claims a regimen-induced longer-lasting metabolic change.
- Claim 3: at least one modification persists for at least one month after cessation.
- Claim 15: prolactin rhythm corresponds substantially on a long-term basis after cessation.
- Claim 21: at least one modification persists over the long term after cessation.
Claim 15 is rhythm-focused, not only endpoint-focused, which can matter where post-treatment biomarkers are contested.
Neural phase oscillations and glucocorticosteroid rhythm: what is claimed?
The patent advances a specific mechanistic framing beyond prolactin suppression.
- Claim 22: period sufficient to modify and reset neural phase oscillations controlling at least one of prolactin and glucocorticosteroid bloodstream levels.
- Claim 27: same reset concept extended to glucocorticosteroid control.
- Claim 34: similar extension for neural phase oscillations controlling prolactin and glucocorticosteroid.
This narrows the “story” of the invention but also adds claim language that could be argued as requiring functional rhythmic reset sufficient to change glucocorticosteroid rhythms.
How broad is the overall “prolactin-inhibiting compound” concept?
At the broadest level, Claim 1 includes “prolactin-inhibiting compound” without restricting to dopamine agonists. However, most practical scope is narrowed quickly in dependent claims to dopamine agonists and to a defined list of ergoline class compounds.
Scope map (what must be true for infringement of different claim layers):
| Claim layer |
Must the compound be a dopamine agonist? |
Must it be in the listed ergoline set? |
Must timing match prolactin peak reference? |
Must dosing fall in 3-100 µg/lb? |
Must duration be within 10-150 or 30-150 days? |
Must effects persist post-cessation? |
| Claim 1 |
Not required |
Not required |
Not required |
Not required |
Not required |
Not required |
| Claim 2 / 13 / 20 / 26 / 32 |
Required |
Not required |
Not required |
Not required |
Not required |
Not required |
| Claims with “selected from group” |
Required |
Required |
Not required |
Not required |
Not required |
Not required |
| Claims with peak timing window (8, 19) |
Required |
Not required (unless layered via other deps) |
Yes: 1-10 hours after peak |
Required (19, 20) |
Not required (unless layered) |
Not required (unless layered via deps) |
| Claims with dose range (4, 6, 14, 19, 35) |
Required |
Not required |
Not required |
Yes |
Not required |
Not required |
| Claims with persistence (3, 15, 21, 33) |
Required |
Not required |
Not required |
Not required |
Not required |
Yes |
| Neural oscillation reset (22, 27, 34) |
Required |
Not required |
Not required |
Not required |
Not required |
Not required |
The table captures the effective narrowing mechanics of the claim set: the patent is broad at the first layer (prolactin inhibition timed daily for glucose endpoints) but tightens rapidly through dependent constraints.
Patent landscape implications: where this claim set creates pressure
The landscape for US method claims like these is shaped less by whether bromocriptine was known and more by whether later parties follow the same combination of:
- prolactin inhibition,
- timed daily dosing relative to prolactin rhythm,
- and durable metabolic outcomes,
often within the dose range and duration window.
High-risk design zones under this patent’s claim grammar:
- Dopamine agonist (especially bromocriptine) used for type 2 diabetes or insulin resistance with a regimen that explicitly times dosing relative to prolactin peak in a lean insulin-sensitive reference.
- Regimens claiming long-term persistence after cessation (one-month persistence or “substantially correspond long-term” rhythm correspondence).
- Regimens framed around rhythm/neural oscillation reset including glucocorticosteroid rhythm claims.
Lower-risk zones (not claimed as such):
- Prolactin lowering without the timing relative to prolactin peak and without durability language.
- Use of non-dopamine-agonist prolactin inhibitors, unless they fit Claim 1’s dopamine-agnostic layer and still satisfy the “timed daily” and endpoint requirements.
- Dosing regimens outside the explicit dopamine-agonist dependent ranges (3-100 µg/lb and 30-150 days), unless infringement is asserted under broader layers.
What is the practical “scope of protection” for bromocriptine programs?
Because bromocriptine is enumerated, and because multiple dependent claims are compatible with bromocriptine, a bromocriptine-derived clinical program risks claim coverage if it uses:
- once-daily prolactin suppression,
- timed to manipulate prolactin rhythm,
- with glucose metabolic improvements and possible persistence post-cessation,
- and (in several dependents) dosing in the 3-100 µg/lb and 30-150 day windows.
Key Takeaways
- US 5,468,755 protects a regimen concept, not just a drug: timed daily prolactin inhibition to improve insulin resistance and diabetes-related outcomes, with multiple claim layers requiring dopamine agonists.
- The highest specificity is timing relative to prolactin physiology: administer 1 to 10 hours after prolactin peak in a lean insulin-sensitive reference subject (same species and sex).
- The claim set includes durability requirements: at least one month post-cessation persistence and long-term prolactin rhythm correspondence.
- The patent enumerates an ergoline/dopamine-agonist set and repeatedly names bromocriptine, making bromocriptine-based diabetes and metabolic rhythm programs the most aligned with the claimed scope.
- Neural phase oscillation reset language extends beyond prolactin, capturing prolactin and glucocorticosteroid rhythm control as claimed functional endpoints.
FAQs
1) Does US 5,468,755 cover any prolactin-inhibiting compound, or only dopamine agonists?
It starts broad in Claim 1 (prolactin-inhibiting compound) but multiple dependent claims require the compound to be a dopamine agonist.
2) What timing constraint is most distinctive in the claim set?
The 1 to 10 hour window after the prolactin bloodstream level peaks in a lean, insulin-sensitive reference subject (Claims 8 and 19).
3) What dose and duration ranges are repeatedly enforced in dependent claims?
Dose: about 3 to about 100 micrograms per pound of body weight. Duration: about 10 to about 150 days, with multiple dependent claims specifying about 30 to about 150 days.
4) Does the patent require long-term effects after stopping the drug?
Several dependents do. Claims 3, 15, and 21 require persistence over at least a month and/or long-term correspondence after cessation.
5) Is bromocriptine explicitly included?
Yes. Bromocriptine is named in multiple dependent claims (Claims 10, 18, 24, 29, and 39) within the enumerated dopamine agonist list.
References
[1] US Patent 5,468,755, “Method for modifying or regulating glucose metabolism by prolactin inhibition,” claims provided in the user prompt.
